WuXi XDC Celebrated as the Best CDMO and CRO in the Industry for Consecutive Years #China #Shanghai #CDMO #CRO #WuXi_XDC
@newsen.bsky.social
@newsen.bsky.social
@newsramp.comScinai Immunotherapeutics (NASDAQ: SCNI) announces ~$4M private placement and warrant inducement deal to expand its CDMO platform and advance its immunotherapy pipeline. Transactions expected to close around Oct. 15, 2026. #Biotech #CDMO
@outsourcedpharma.bsky.socialRaw materials can look routine until they’re the reason production stops. Outsourced Pharma’s Deputy Editor examines five assumptions sponsors should challenge before variability, supplier changes or release delays derail a CDMO campaign.
www.outsourcedpharma.com/doc/five-raw...
@newsen.bsky.socialScinai Immunotherapeutics Secures $4 Million Financing to Drive Growth Strategies #Scinai_Immunotherapeutics #Israel #Jerusalem #Biopharmaceutical #CDMO
@newsramp.comScinai Immunotherapeutics (NASDAQ: SCNI) secures a $5.1M clinical manufacturing deal for an oncology program, pushing total committed orders to $7.6M — a 300% jump from year-end 2025. Additional opportunities worth $5.85M are on the horizon. #Biotech #CDMO
@mshiva.bsky.socialBring quality events, documents and training together with epiq by Caliber. Connect workflows from process changes to document revisions and required training in one enterprise platform.
Explore: caliberuniversal.com/solutions/en...
#PharmaQuality #Caliber #CDMO #Pharmacutical #Manufacturing #CMO
@newsen.bsky.socialScinai Expands Its CDMO Footprint with Significant $5.1 Million Agreement #Israel #Jerusalem #Biopharmaceutical #Scinai #CDMO
@dominic-tyer.bsky.socialIs big always better in manufacturing and how do you select the right CDMO partner in this age of consolidation? That was one of the debates at CPHI Milan last week.
@newsramp.comFamiCord's Bramble Bio has signed a manufacturing deal with VERIGRAFT to produce personalized tissue-engineered vein P-TEV for the pivotal Phase II/III trial TECVI-2, valued in the low single-digit millions of euros. Trial expected to begin Q1 2027. #CDMO #CellTherapy
@dominic-tyer.bsky.socialModerna outlined its COVID-era manufacturing lessons and how the biotech works with CDMOs at CPHI Milan this week
@aganitha.aiMuch of the scientific and technical work around #CDMO selection in a #Biopharma still happens outside ERP & procurement systems - in PDFs, spreadsheets, emails & manual reviews.
At Aganitha, we are using #AI to streamline these workflows.
Know more at www.aganitha.ai/blogs/cdmo-g...
@outsourcedpharma.bsky.socialBluesky
RNA therapeutics are advancing fast. The outsourcing ecosystem has to keep up.
Chief Editor Louis Garguilo looks at how CDMOs, academia, automation and new service models could reshape RNA development and manufacturing.
www.outsourcedpharma.com/doc/cdmos-co...
#RNA #CDMO #Biopharma
@newsen.bsky.socialROIS Unveils New Brand Identity at CPHI Milan 2026 Event #Italy #Milan #CDMO #ROIS #CPHI_Milan
@newsen.bsky.socialROIS Unveils New Brand Identity and Website at CPHI Milan 2026 #Italy #Milan #CDMO #ROIS #CPHI_Milan
@new3rd.bsky.social@newsen.bsky.socialAjinomoto Bio-Pharma Services Launches a Renewed Global Brand Focused on Specialization #Japan #Tokyo #CDMO #Ajinomoto #Bio-Pharma_Services
@outsourcedpharma.bsky.socialYour CDMO can make the product. But can the market afford it?
@drjbug.bsky.social examines why affordability should shape formulation, packaging and outsourcing decisions long before launch.
www.outsourcedpharma.com/doc/your-cdm...
#CDMO #Biopharma #pharmamanufacturing
@outsourcedpharma.bsky.socialJoin me tomorrow for a great, live discussion!
Complimentary registration, thanks to Douglas Pharmaceuticals:
event.on24.com/wcc/r/547759...
@nikolospharma.bsky.social
@nikolospharma.bsky.social